Comparison of T₁Rho MRI, Glucose Metabolism, and Amyloid Burden Across the Cognitive Spectrum: A Pilot Study

The pathological cascades associated with the development of Alzheimer’s disease (AD) have a common element: acidosis. T₁rho MRI is a pH-sensitive measure, with higher values associated with greater neuropathological burden. The authors investigated the relationship between T₁rho imaging and AD-associated pathologies as determined by available diagnostic imaging techniques.

Twenty-seven participants (men, N=13, women, N=14; ages 55–90) across the cognitive spectrum (healthy control subjects [HCs] with normal cognition, N=17; participants with mild cognitive impairment [MCI], N=7; participants with mild AD, N=3) underwent neuropsychological testing, MRI (T₁-weighted and T₁rho [spin-lattice relaxation time in the rotating frame]), and positron emission tomography imaging ([¹¹C]Pittsburg compound B for amyloid burden [N=26] and [¹⁸F]fluorodeoxyglucose for cerebral glucose metabolism [N=12]). The relationships between global T₁rho values and neuropsychological, demographic, and imaging measures were explored.

Global mean and median T₁rho were positively associated with age. After controlling for age, higher global T₁rho was associated with poorer cognitive function, poorer memory function (immediate and delayed memory scores), higher amyloid burden, and more abnormal cerebral glucose metabolism. Regional T₁rho values, when controlling for age, significantly differed between HCs and participants with MCI or AD in select frontal, cingulate, and parietal regions.

Higher T₁rho values were associated with greater cognitive impairment and pathological burden. T₁rho, a biomarker that varies according to a feature common to each cascade rather than one that is unique to a particular pathology, has the potential to serve as a metric of neuropathology, theoretically providing a measure for assessing pathological status and for monitoring the neurodegeneration trajectory.